Literature DB >> 22545174

A research and development agenda for the control and elimination of human helminthiases.

Jürg Utzinger.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22545174      PMCID: PMC3335882          DOI: 10.1371/journal.pntd.0001646

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


× No keyword cloud information.
In this issue of PLoS Neglected Tropical Diseases, the Disease Reference Group on Helminth Infections (DRG4) has put forward a collection of eight reviews that, taken together, outline a compelling research and development agenda for the control and elimination of helminth diseases of humans (http://www.ploscollections.org/helminths [1]–[8]). Emphasis is placed on six major helminth infections: (i) soil-transmitted helminthiasis; (ii) schistosomiasis; (iii) lymphatic filariasis; (iv) onchocerciasis; (v) food-borne trematodiasis; and (vi) cysticercosis/taeniasis. Selection of these helminthiases is justified on multiple grounds. Firstly, as shown in Table 1, more than half of the world's population is at risk of one or several of these helminthiases, and hundreds of millions of people are currently infected. Secondly, consequences of the mainly long-term chronic infection include suffering, stigmatisation, subtle and gross morbidity (e.g., anaemia, limb deformations and blindness), and premature death, hence causing an intolerable global burden [9]–[17]. These features, in turn, exacerbate poverty [18]–[20]. Thirdly, there is growing commitment at all levels—from local communities to politicians, philanthropic organisations, and civil society—to control and eventually eliminate/eradicate the major human helminthiases.
Table 1

Helminth Infections Emphasised by DRG4 for Development of a Research Agenda for Control and Elimination.

Helminth InfectionCausative Agent(s)At-Risk Population (Millions)No. of People Infected (Millions)No. of People with Morbidity (Millions)No. of Deaths per Year (Thousands)Global Burden (Thousand DALYs)Reference(s)
Soil-transmitted helminthiasis
Ascariasis Ascaris lumbricoides 5,416807–1,2213503–601,817–10,500 [10], [11], [17]
Trichuriasis Trichuris trichiura 5,307604–7952203–101,006–6,400 [10], [11], [17]
Hookworm infection Ancylostoma duodenale and Necator americanus 5,346576–7401503–6559–22,100 [10], [11], [17]
Strongyloidiasis Strongyloides stercoralis n.d.30–100n.d.n.d.n.d. [10]
Lymphatic filariasis Wuchereria bancrofti, Brugia malayi, and B. timori >1,0001204305,777 [11], [14]
Schistosomiasisa Schistosoma haematobium, S. japonicum, and S. mansoni 77920712015–2801,702–4,500 [11], [12]
Food-borne trematodiasis
Clonorchiasis Clonorchis sinensis 60115.31.15.6275 [13], [16]
Paragonimiasis Paragonimus spp.29223.25.30.2197 [13], [16]
Fascioliasis Fasciola gigantica and F. hepatica 912.60.3035 [13], [16]
Opisthorchiasis Opisthorchis felineus and O. viverrini 808.40.31.374 [13], [16]
Intestinal fluke infections Echinostoma spp., Fasciolopsis buski, Metagonimus spp., and Heterophyidae n.d.6.70.9084 [13], [16]
Onchocerciasis Onchocerca volvulus 12037n.d.0.05 (in the OCP area)484 [9], [14]
Cysticercosis/taeniasis Taenia solium and T. saginata n.d.n.d.n.d.n.d.>2,000 [15]

Listed are the three main schistosome species parasitising humans; of lesser importance are S. guineenisis and S. intercalatum (both restricted to West and Central Africa) and S. mekongi (restricted to Cambodia and Lao PDR).

DALY, disability-adjusted life year; n.d., not determined; OCP, Onchocerciasis Control Programme.

Listed are the three main schistosome species parasitising humans; of lesser importance are S. guineenisis and S. intercalatum (both restricted to West and Central Africa) and S. mekongi (restricted to Cambodia and Lao PDR). DALY, disability-adjusted life year; n.d., not determined; OCP, Onchocerciasis Control Programme. Figure 1 shows that the six helminthiases are at distinctively different stages of control and elimination with geographical idiosyncrasies for some of them [21]. Several helminthiases have been targeted for elimination (e.g., lymphatic filariasis and onchocerciasis in the Americas), and progress made thus far gives hope that this goal can indeed be achieved by 2015 or 2020 if certain conditions are met [14], [21]. For schistosomiasis and soil-transmitted helminthiasis, discussions are escalating to shift the focus from control to elimination [22], [23], and in Africa, the African Programme for Onchocerciasis Control (APOC) is also moving towards this goal [24]. The pivotal role of research, coupled with teaching and training of strong cadres of researchers from endemic settings as essential backbones and platforms to design, implement, and adapt the control and elimination agenda for major helminthiases as well as other tropical diseases, cannot be emphasised enough [25]–[27].
Figure 1

Stages of control/elimination of the six helminthiases emphasised by DRG4.

The schematic representation shows the different stages of a control programme (from morbidity to transmission control), including the extreme ends (i.e., no control, extent of the problem yet to be determined on the far left; and elimination on the far right). Colour codes of horizontal lines: black, global; blue, Latin America and Caribbean; red, sub-Saharan Africa; brown, Middle East and North Africa; green, Asia. Dashed lines indicate that, in some counties within a sub-region (or globally), the control/elimination is less or more advanced than in the sub-region (or globally) overall.

Stages of control/elimination of the six helminthiases emphasised by DRG4.

The schematic representation shows the different stages of a control programme (from morbidity to transmission control), including the extreme ends (i.e., no control, extent of the problem yet to be determined on the far left; and elimination on the far right). Colour codes of horizontal lines: black, global; blue, Latin America and Caribbean; red, sub-Saharan Africa; brown, Middle East and North Africa; green, Asia. Dashed lines indicate that, in some counties within a sub-region (or globally), the control/elimination is less or more advanced than in the sub-region (or globally) overall. In 2007/2008, the Special Programme for Research and Training in Tropical Diseases (TDR), based at and executed by the World Health Organization (WHO), and co-sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and WHO, initiated a network of disease-specific and thematic reference groups (DRGs/TRGs). DRG4 was particularly prolific, as witnessed in the collection of authoritative reviews presented here. This accompanying editorial summarises the goal, objectives and expected outcomes of the DRGs/TRGs global research “think tank”. Next, light is shed on the composition of DRG4, its mode of operation and its first outputs. It is then argued that PLoS Neglected Tropical Diseases is an appropriate outlet for the studies reviewed and synthesised by DRG4. Indeed, open access to the identified and ranked research priorities by all stakeholders is a major asset and is likely to reinforce the control and elimination agenda of the major helminthiases.

A Global Research “Think Tank”

The idea to create a global network of DRGs and TRGs as a major international research “think tank” stems from the fourth external review of TDR that took place between February 2005 and May 2006 [28]. The role and operation of this “think tank” were incorporated into the 10-year strategic plan of TDR, which is endorsed by WHO. A key recommendation of the aforementioned external review was that TDR should shift its emphasis from pursuing a model of disease portfolio (“neglected diseases”) [29] to infectious diseases of poverty-related research needs (“needy populations”). As a result of this thinking, the 10-year strategy and underlying business plan of TDR recommended two strong pillars to position and further enhance the organisation's strategic advantages in a rapidly changing global landscape of funding, research and development: (i) knowledge management that should lead to the concept of stewardship, and (ii) capacity building that should foster empowerment [30]. Conceptualised in 2007/2008, a total of 10 reference groups, six of them with a disease-specific focus, and the remaining four with a thematic and cross-cutting emphasis, were initiated [2] (Table 2; see also Table S1 in [2]). Each reference group comprises 10–14 international experts. Groups are chaired and co-chaired by renowned scientists, at least one of whom is based in a developing country. A competitively selected young career research fellow is offered the opportunity to be part of the group, primarily pursuing research within the realm of the group, but also charged with some limited operational and managerial tasks to ascertain smooth operation of the groups. The reference groups are hosted by WHO country offices in Africa, Asia, and Latin America.
Table 2

Global Network of Disease-Specific Reference Groups (DRGs) and Thematic Reference Groups (TRGs).

DRG and TRGDisease(s) or Thematic FocusHosting Institution(s) and Country(ies)
DRG1MalariaWHO Regional Office for Africa (AFRO), Republic of the Congo
DRG2Tuberculosis, leprosy, and Buruli ulcerWHO Country Office for the Philippines
DRG3Chagas disease, human African trypanosomiasis, and leishmaniasisWHO Country Offices for Sudan and Brazil
DRG4 Helminthiases African Programme for Onchocerciasis Control (APOC), Burkina Faso
DRG5Dengue and emerging viral diseasesWHO Country Office for Cuba
DRG6Zoonosis and marginalised infectious diseasesWHO Regional Office for Easter and Mediterranean (EMRO), in collaboration with WHO Country Office for Egypt
TRG1Social science and genderWHO Country Office for Ghana
TRG2Innovation and biotechnology platformsWHO Country Office for Thailand
TRG3Implementation and health systems researchWHO Country Office for Nigeria
TRG4Environment, agriculture and human healthWHO Country Office for the People's Republic of China

In 2007/2008, the Special Programme for Research and Training in Tropical Diseases (TDR) set up a global network of DRGs and TRGs as an independent “think tank” of international experts. The groups met regularly to review, debate, and synthesise existing information, including stakeholder consultation. The ultimate aim was to establish and strengthen an evidence base on infectious diseases of poverty and cross-cutting themes, including identifying knowledge gaps and current research priorities.

In 2007/2008, the Special Programme for Research and Training in Tropical Diseases (TDR) set up a global network of DRGs and TRGs as an independent “think tank” of international experts. The groups met regularly to review, debate, and synthesise existing information, including stakeholder consultation. The ultimate aim was to establish and strengthen an evidence base on infectious diseases of poverty and cross-cutting themes, including identifying knowledge gaps and current research priorities. As per TDR's latest 10-year strategy and vision, the global network of DRGs and TRGs operate within the guiding principles of knowledge management and capacity building, thus emphasising stewardship and empowerment. The specific objectives are to systematically review, debate, and synthesise available information and to define and rate research priorities. This is facilitated by regular meetings (it was initially planned that the groups would meet once a year for 3–5 days), usually in the hosting country of a specific group. Broad stakeholder consultation, usually at the outset of the meetings, was adopted as an integral part of the modus operandi of the groups.

The Disease Reference Group on Helminth Infections (DRG4)

DRG4 initially comprised 14 individuals. The group is chaired by Sara Lustigman at the Lindsley F. Kimball Research Institute, New York Blood Center in New York, United States of America. Boakye A. Boatin serves as the co-chair, currently affiliated with two institutions, the Institute of Parasitology, McGill University (Montreal, Canada), and the Noguchi Memorial Institute of Medical Research, University of Ghana (Legon, Ghana). The career research fellow is based at the Council for Scientific and Industrial Research, Water Research Institute, in Ghana. The writing core team includes Sara Lustigman, Boakye A. Boatin, María-Gloria Basáñez (United Kingdom), and Roger K. Prichard (Canada). The geographical representation of the remaining nine members reveals two from Africa (Côte d'Ivoire and Ghana), two from Asia (Thailand and People's Republic of China), two from Latin America (Brazil and Peru), two from Oceania (Australia), and one from the Middle East (Egypt). At the outset, the group identified research gaps and pursued a multi-criteria assessment, including stakeholder consultation, and Delphi approach that ultimately resulted in a consolidated list of the 10 top research priorities. This forms the “white paper” of the DRG4, i.e., recognising and pursuing these priorities in order to achieve control and elimination of major human helminthiases. This “white paper” is co-authored by the entire group [2]. Next, an in-depth analysis outlines the problem of human helminthiases, emphasising the omnipresence of single and multiple species parasitic worm infections and their intricate relationship with poverty [1]. Visualising this collection as house, the reviews highlighting the problem of human helminthiases, and issues towards control and elimination, are like the foundation upon which the building is erected (Figure 2). Key proposed responses for the helminthiases control and elimination agenda are reviewed in four separate pieces that are the main building blocks of the house. These include basic research and enabling technologies [3], new and improved intervention tools and strategies, such as drugs, vaccines, and for some of the helminthiases also vector control [6], diagnostics [4], and mathematical modelling to inform policy and reinforce research [5]. Understanding social-ecological contexts, environmental determinants, and health systems forms the first layer of the roof [7]. Health research and capacity building in developing country settings is of such pivotal importance that it is layered on top of a well-built house, and hence reinforces the agenda [8].
Figure 2

A research agenda for the control and elimination of major helminthiasis put forth by DRG4.

This figure synthesises the key written outputs from DRG4, visualising this collection of eight reviews as a house (strong foundation, major building blocks and a two-layered roof).

A research agenda for the control and elimination of major helminthiasis put forth by DRG4.

This figure synthesises the key written outputs from DRG4, visualising this collection of eight reviews as a house (strong foundation, major building blocks and a two-layered roof). It is, perhaps, interesting to note that key research and development (R&D) issues have already been discussed in connection with a malaria eradication research agenda (malERA). Facilitated by a 2-year broadly integrative and iterative process led by a core team, and assisted by various experts groups and involving more than 250 scientists, programme managers and decision-makers from the public and private sectors in a series of consultations, the malERA went live in a special issue of PLoS Medicine in early 2011 [27]. Similar R&D issues were identified in parallel by the malERA and the series presenting the research agenda for helminth infections of humans. Once the collection of malERA papers came out, they served as an inspiration to also publish the comprehensive R&D agenda pertaining to human helminthiases in a collection of reviews, and PLoS Neglected Tropical Diseases was deemed a suitable outlet. Both agendas feature basic science and enabling technologies [3], [31], diagnoses and diagnostics [4], [32], modelling [5], [33], and health systems issues [7], [34]. While the helminthiases agenda has a single chapter on interventions (due to the fact that, for instance, interventions such as anti-helminth vaccines are in earlier stages of development for use in humans [35]), in the malERA, there are three separate contributions for interventions: drugs, vaccines, and vector control [36]–[38]. This difference further emphasises the neglect in R&D funding for novel and repositioned intervention tools to control human helminth infections as opposed to malaria [39]. Additionally, the malERA views the issues of monitoring, evaluation, and surveillance (the latter further developed as “surveillance as an intervention”) of such great importance that space is given for a full contribution [40]. Together with a piece on cross-cutting issues for eradication, lessons learned from the first malaria eradication era in the 1950s and 1960s, and the aforementioned umbrella [27], the malERA certainly is a key resource for developing control and elimination/eradication agendas for human infectious diseases, including human helminthiases. However, the research agenda for helminthiases is unique in its contribution of a separate article fully considering the issues of capacity building for health research and disease control in endemic countries [8], which is absent in the malERA collection. Both collections therefore should be considered together as prime examples of major outputs produced by think tanks, driven by core writing teams and stakeholder engagement in the current global efforts to help control and eliminate poverty-related diseases [21].

Going Live in PLoS Neglected Tropical Diseases

In terms of writing, the various DRGs and TRGs were charged to produce annual reports. Additionally, the groups were requested to have these reports further developed into stand-alone comprehensive Technical Report Series, to be published by the WHO. Unfortunately, at the time these reports were submitted to TDR, the organisation sailed through troubled waters, delaying internal processing and external peer review. Yet, there is new traction and it is hoped that the planned WHO Technical Report Series will soon come to bear. In the meantime, the Disease Reference Group on Zoonoses and Marginalized Infectious Diseases (DRG6) disseminated a most useful overview article through the open-access journal Parasites & Vectors [41]. The efforts made by DRG4 to produce no less than eight major reviews are commended and PLoS Neglected Tropical Diseases clearly is an appropriate outlet for this collection of articles. To wit, within 2–3 years after the launch of PLoS Neglected Tropical Diseases in late 2007, this open-access vehicle established itself as the leading peer-reviewed journal in tropical medicine. Two seminal papers published in 2005 and 2006 provided an initial list of 15 neglected tropical diseases, the majority of which were due to helminth infections [42], [43]. Indeed, all of the six helminthiases emphasised by DRG4 were part of the initial scope of PLoS Neglected Tropical Diseases. Meanwhile, the scope of the journal has broadened considerably [44], and now also includes a growing number of bacterial, protozoal, viral, and ectoparasitic infections, but helminthiases still figure prominently. Indeed, as shown in Table 3, more than 20% of the over 1,300 original articles, reviews, and front-matter pieces focus on helminth infections.
Table 3

Number and Percentage of Helminth-Related Articles Published in PLoS Neglected Tropical Diseases.

Search StrategyNo. (%) of Hits
PLoS Neglected Tropical Diseases 1335 (100)
Protozoan infections294 (22.0)
Helminth infections 277 (20.7)
Viral infections212 (15.9)
Bacterial infections185 (13.9)
Fungal infections11 (0.8)
Ectoparasitic infections0
Helminths (parasitic worms) 481 (36.0)
Trematodes 103 (7.7)
Nematodes 101 (7.6)
Cestodes 26 (1.9)
Helminthic diseases260 (19.5)
Schistosomiasis 138 (10.3)
Lymphatic filariasis 57 (4.3)
Soil-transmitted helminthiasis 36 (2.7)
Onchocerciasis 34 (2.5)
Echinococcosis25 (1.9)
Cysticercosis 23 (1.7)
Taeniasis 20 (1.5)
Toxocariasis7 (0.5)
Loiasis6 (0.4)
Food-borne trematodiasis 1 (0.1)
Dracunculiasis0
Important helminth species
Schistosoma mansoni 80 (6.0)
Hookworm 49 (3.7)
Schistosoma japonicum 39 (2.9)
Trichuris trichiura 32 (2.4)
Ascaris lumbricoides 31 (2.3)
Brugia malayi 21 (1.6)
Strongyloides stercoralis 17 (1.3)
Taenia solium 15 (1.1)
Wuchereria bancrofti 14 (1.0)
Onchocerca volvulus 13 (1.0)
Clonorchis sinensis 8 (0.6)
Fasciola hepatica 8 (0.6)
Opisthorchis viverrini 6 (0.4)

Search performed on PubMed on March 15, 2012, using the advanced search builder. In a first step, the term “PLoS Neglected Tropical Diseases” was entered in the field “journal”, which revealed 1,335 hits. In subsequent steps, helminth-specific terms were added using the Boolean operator “AND”. Bold text in the table indicates parasites, parasitic infections, and diseases covered by the Disease Reference Group on Helminth Infections (DRG4).

Search performed on PubMed on March 15, 2012, using the advanced search builder. In a first step, the term “PLoS Neglected Tropical Diseases” was entered in the field “journal”, which revealed 1,335 hits. In subsequent steps, helminth-specific terms were added using the Boolean operator “AND”. Bold text in the table indicates parasites, parasitic infections, and diseases covered by the Disease Reference Group on Helminth Infections (DRG4).

Lessons Learned and Next Steps

Sixty-five years after the landmark publication of Norman R. Stool entitled “This Wormy World” [45], it is clear that helminthiases are still widespread and continue to pose a huge public health problem. Indeed, a situation analysis reveals that more than half of the word's population is at risk of helminth infection, more than a billion people are currently infected, often with multiple species, and helminthiases are rife where poverty and malnutrition prevail, in the face of lack of access to basic infrastructure (e.g., clean water and sanitation) and hygiene [17], [20], [46]. These facts form the foundation of the current article collection [1], [2]. Responses on how to control and eventually eliminate human helminthiases require ethically, technically and scientifically sound research to improve current tools and strategies, as summarised in the present helminthiasis agenda [2]–[6]. Research and capacity building must accompany the entire process and innovation is key to developing and validating the next generation of tools and strategies [8]. For example, there is a need for developing rapid and inexpensive integrated mapping approaches for those helminthiases where the extent of the problem is not yet appreciated [47]. The recent development of high-resolution, spatially explicit global databases for helminthiases and other neglected tropical diseases provides an exciting new opportunity for targeting control interventions, and subsequent monitoring, evaluation, and surveillance [48], [49]. Importantly, once the emphasis shifts from morbidity control towards transmission control and finally local elimination, the need for highly accurate diagnostics tools must be stressed. Indeed, the diagnostics must be adapted to the current stage of a control programme [50]. Moreover, lessons learned from past successful helminthiases control and elimination programmes emphasise the need for integrated approaches with close collaboration between different sectors (e.g., health, education, and water) and long-term political commitment [51]–[53]. These issues must be seen in rapidly changing demographic, health systems, and social-ecological contexts [7]. A deep understanding at different spatial and temporal scales is mandatory so that some of the most ancient afflictions of humankind can be consigned to history in the not too distant future.
  50 in total

Review 1.  Rescuing the bottom billion through control of neglected tropical diseases.

Authors:  Peter J Hotez; Alan Fenwick; Lorenzo Savioli; David H Molyneux
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

2.  Diagnostic dilemmas in helminthology: what tools to use and when?

Authors:  Robert Bergquist; Maria Vang Johansen; Jürg Utzinger
Journal:  Trends Parasitol       Date:  2009-03-09

Review 3.  Food-borne trematodiases.

Authors:  Jennifer Keiser; Jürg Utzinger
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

4.  Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution.

Authors:  J Utzinger; G Raso; S Brooker; D De Savigny; M Tanner; N Ornbjerg; B H Singer; E K N'goran
Journal:  Parasitology       Date:  2009-11       Impact factor: 3.234

Review 5.  Parasites and poverty: the case of schistosomiasis.

Authors:  Charles H King
Journal:  Acta Trop       Date:  2009-12-04       Impact factor: 3.112

Review 6.  Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa.

Authors:  S Brooker; N B Kabatereine; J O Gyapong; J R Stothard; J Utzinger
Journal:  Parasitology       Date:  2009-05-19       Impact factor: 3.234

Review 7.  A research agenda for malaria eradication: vaccines.

Authors: 
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

8.  Prevention, control, and elimination of neglected diseases in the Americas: pathways to integrated, inter-programmatic, inter-sectoral action for health and development.

Authors:  John C Holveck; John P Ehrenberg; Steven K Ault; Rocio Rojas; Javier Vasquez; Maria Teresa Cerqueira; Josefa Ippolito-Shepherd; Miguel A Genovese; Mirta Roses Periago
Journal:  BMC Public Health       Date:  2007-01-17       Impact factor: 3.295

9.  Two years after the Fourth External Review: TDR moves forward with a new vision and strategy.

Authors:  Robert G Ridley; Peter Ndumbe; Rolf Korte
Journal:  PLoS Negl Trop Dis       Date:  2008-11-25

10.  TDR thirty years on: taking stock and envisioning the future for the Special Programme for Research and Training in Tropical Diseases.

Authors:  Abdallah S Daar; Susan Reynolds Whyte; Mohamed S Abdullah; Hu Ching-Li; Stephen L Hoffman; Martine Berger
Journal:  PLoS Negl Trop Dis       Date:  2008-11-25
View more
  19 in total

1.  Prevalence of soil-transmitted helminths in remote villages in East Kwaio, Solomon Islands.

Authors:  Humpress Harrington; Richard Bradbury; James Taeka; James Asugeni; Vunivesi Asugeni; Tony Igeni; John Gwala; Lawrence Newton; Chillion Evan Fa; Fawcett Laurence Kilivisi; Dorothy Esau; Angelica Flores; Elmer Ribeyro; Daisy Liku; Alwin Muse; Lyndel Asugeni; Jeptha Talana; Jennifer Shield; David J MacLaren; Peter D Massey; Reinhold Muller; Rick Speare
Journal:  Western Pac Surveill Response J       Date:  2015-08-10

2.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.

Authors:  Kevin C Kobylinski; Haoues Alout; Brian D Foy; Archie Clements; Poom Adisakwattana; Brett E Swierczewski; Jason H Richardson
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

3.  Effect of combinations of marketed human anthelmintic drugs against Trichuris muris in vitro and in vivo.

Authors:  Jennifer Keiser; Lucienne Tritten; Roberto Adelfio; Mireille Vargas
Journal:  Parasit Vectors       Date:  2012-12-11       Impact factor: 3.876

Review 4.  Risk profiling of schistosomiasis using remote sensing: approaches, challenges and outlook.

Authors:  Yvonne Walz; Martin Wegmann; Stefan Dech; Giovanna Raso; Jürg Utzinger
Journal:  Parasit Vectors       Date:  2015-03-17       Impact factor: 3.876

Review 5.  Frontiers of parasitology research in the People's Republic of China: infection, diagnosis, protection and surveillance.

Authors:  Jun-Hu Chen; Hen Wang; Jia-Xu Chen; Robert Bergquist; Marcel Tanner; Jürg Utzinger; Xiao-Nong Zhou
Journal:  Parasit Vectors       Date:  2012-10-04       Impact factor: 3.876

6.  The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.

Authors:  Aprilianto E Wiria; Firdaus Hamid; Linda J Wammes; Maria M M Kaisar; Linda May; Margaretta A Prasetyani; Sitti Wahyuni; Yenny Djuardi; Iwan Ariawan; Heri Wibowo; Bertrand Lell; Robert Sauerwein; Gary T Brice; Inge Sutanto; Lisette van Lieshout; Anton J M de Craen; Ronald van Ree; Jaco J Verweij; Roula Tsonaka; Jeanine J Houwing-Duistermaat; Adrian J F Luty; Erliyani Sartono; Taniawati Supali; Maria Yazdanbakhsh
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

Review 7.  Persistent digestive disorders in the tropics: causative infectious pathogens and reference diagnostic tests.

Authors:  Sören L Becker; Jürg Vogt; Stefanie Knopp; Marcus Panning; David C Warhurst; Katja Polman; Hanspeter Marti; Lutz von Müller; Cedric P Yansouni; Jan Jacobs; Emmanuel Bottieau; Moussa Sacko; Suman Rijal; Fransiska Meyanti; Michael A Miles; Marleen Boelaert; Pascal Lutumba; Lisette van Lieshout; Eliézer K N'Goran; François Chappuis; Jürg Utzinger
Journal:  BMC Infect Dis       Date:  2013-01-24       Impact factor: 3.090

8.  Improving access to anti-schistosome treatment and care in nonendemic areas of China: lessons from one case of advanced schistosomiasis japonica.

Authors:  Da-Bing Lu; Li Zhou; Ying Li
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

9.  Time to tackle clonorchiasis in China.

Authors:  Men-Bao Qian; Ying-Dan Chen; Fei Yan
Journal:  Infect Dis Poverty       Date:  2013-02-19       Impact factor: 4.520

10.  Diagnosis of neglected tropical diseases among patients with persistent digestive disorders (diarrhoea and/or abdominal pain ≥14 days): Pierrea multi-country, prospective, non-experimental case-control study.

Authors:  Katja Polman; Sören L Becker; Emilie Alirol; Nisha K Bhatta; Narayan R Bhattarai; Emmanuel Bottieau; Martin W Bratschi; Sakib Burza; Jean T Coulibaly; Mama N Doumbia; Ninon S Horié; Jan Jacobs; Basudha Khanal; Aly Landouré; Yodi Mahendradhata; Filip Meheus; Pascal Mertens; Fransiska Meyanti; Elsa H Murhandarwati; Eliézer K N'Goran; Rosanna W Peeling; Raffaella Ravinetto; Suman Rijal; Moussa Sacko; Rénion Saye; Pierre H H Schneeberger; Céline Schurmans; Kigbafori D Silué; Jarir A Thobari; Mamadou S Traoré; Lisette van Lieshout; Harry van Loen; Kristien Verdonck; Lutz von Müller; Cédric P Yansouni; Joel A Yao; Patrick K Yao; Peiling Yap; Marleen Boelaert; François Chappuis; Jürg Utzinger
Journal:  BMC Infect Dis       Date:  2015-08-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.